Literature DB >> 15047846

Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.

Jonathan S Towner1, Pierre E Rollin, Daniel G Bausch, Anthony Sanchez, Sharon M Crary, Martin Vincent, William F Lee, Christina F Spiropoulou, Thomas G Ksiazek, Mathew Lukwiya, Felix Kaducu, Robert Downing, Stuart T Nichol.   

Abstract

The largest outbreak on record of Ebola hemorrhagic fever (EHF) occurred in Uganda from August 2000 to January 2001. The outbreak was centered in the Gulu district of northern Uganda, with secondary transmission to other districts. After the initial diagnosis of Sudan ebolavirus by the National Institute for Virology in Johannesburg, South Africa, a temporary diagnostic laboratory was established within the Gulu district at St. Mary's Lacor Hospital. The laboratory used antigen capture and reverse transcription-PCR (RT-PCR) to diagnose Sudan ebolavirus infection in suspect patients. The RT-PCR and antigen-capture diagnostic assays proved very effective for detecting ebolavirus in patient serum, plasma, and whole blood. In samples collected very early in the course of infection, the RT-PCR assay could detect ebolavirus 24 to 48 h prior to detection by antigen capture. More than 1,000 blood samples were collected, with multiple samples obtained from many patients throughout the course of infection. Real-time quantitative RT-PCR was used to determine the viral load in multiple samples from patients with fatal and nonfatal cases, and these data were correlated with the disease outcome. RNA copy levels in patients who died averaged 2 log(10) higher than those in patients who survived. Using clinical material from multiple EHF patients, we sequenced the variable region of the glycoprotein. This Sudan ebolavirus strain was not derived from either the earlier Boniface (1976) or Maleo (1979) strain, but it shares a common ancestor with both. Furthermore, both sequence and epidemiologic data are consistent with the outbreak having originated from a single introduction into the human population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047846      PMCID: PMC374287          DOI: 10.1128/jvi.78.8.4330-4341.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates.

Authors:  T G Ksiazek; P E Rollin; P B Jahrling; E Johnson; D W Dalgard; C J Peters
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting.

Authors:  E M Leroy; S Baize; C Y Lu; J B McCormick; A J Georges; M C Georges-Courbot; J Lansoud-Soukate; S P Fisher-Hoch
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

4.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

5.  Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-02-09       Impact factor: 17.586

6.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

7.  Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

8.  Ebola haemorrhagic fever in Zaire, 1976.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

9.  Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread.

Authors:  R C Baron; J B McCormick; O A Zubeir
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

10.  Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

Authors:  Christian Drosten; Stephan Göttig; Stefan Schilling; Marcel Asper; Marcus Panning; Herbert Schmitz; Stephan Günther
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

View more
  208 in total

1.  Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method.

Authors:  Yohei Kurosaki; Allen Grolla; Aiko Fukuma; Heinz Feldmann; Jiro Yasuda
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Measuring the impact of Ebola control measures in Sierra Leone.

Authors:  Adam J Kucharski; Anton Camacho; Stefan Flasche; Rebecca E Glover; W John Edmunds; Sebastian Funk
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

Review 3.  Bioterrorism and the Role of the Clinical Microbiology Laboratory.

Authors:  Elizabeth Wagar
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 4.  Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins.

Authors:  Masayuki Saijo; Masahiro Niikura; Tetsuro Ikegami; Ichiro Kurane; Takeshi Kurata; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2006-04

5.  Rapid molecular strategy for filovirus detection and characterization.

Authors:  Junhui Zhai; Gustavo Palacios; Jonathan S Towner; Omar Jabado; Vishal Kapoor; Marietjie Venter; Allen Grolla; Thomas Briese; Janusz Paweska; Robert Swanepoel; Heinz Feldmann; Stuart T Nichol; W Ian Lipkin
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

6.  Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases.

Authors:  M Kariuki Njenga; Janusz Paweska; Rose Wanjala; Carol Y Rao; Matthew Weiner; Victor Omballa; Elizabeth T Luman; David Mutonga; Shanaaz Sharif; Marcus Panning; Christian Drosten; Daniel R Feikin; Robert F Breiman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

7.  Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012.

Authors:  C G Albariño; T Shoemaker; M L Khristova; J F Wamala; J J Muyembe; S Balinandi; A Tumusiime; S Campbell; D Cannon; A Gibbons; E Bergeron; B Bird; K Dodd; C Spiropoulou; B R Erickson; L Guerrero; B Knust; S T Nichol; P E Rollin; U Ströher
Journal:  Virology       Date:  2013-05-25       Impact factor: 3.616

8.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy D Flietstra; Shelley Campbell; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Christopher J Kratochvil; Peter C Iwen; Philip W Smith; Rafi Ahmed; Stuart T Nichol; Christina F Spiropoulou
Journal:  Clin Infect Dis       Date:  2016-06-27       Impact factor: 9.079

9.  Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.

Authors:  Jerry F Brown; John M Dye; Sam Tozay; Gertrude Jeh-Mulbah; David A Wohl; William A Fischer; Coleen K Cunningham; Kathleen Rowe; Peter Zacharias; James van Hasselt; David A Norwood; Nathan M Thielman; Samantha E Zak; David L Hoover
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

10.  Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.

Authors:  Anita K McElroy; Bobbie R Erickson; Timothy D Flietstra; Pierre E Rollin; Stuart T Nichol; Jonathan S Towner; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.